Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.46 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.46 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.46 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31346720 | 1.00 | PDPK1 (0.54) | PDPK1CNR1IDO1HTTGGPS1 | |
| SCHEMBL10900027 | 0.89 | ACLY (0.56) | PDPK1CNR1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL7330078 | 0.85 | PDPK1 (0.56) | PDPK1CNR1IDO1GGPS1HPGD | |
| SCHEMBL28179666 | 0.84 | HSD17B10 (0.42) | PDPK1 | |
| SCHEMBL2489075 | 0.83 | PDPK1 (0.55) | PDPK1CNR1IDO1GGPS1HPGD | |
| SCHEMBL30567601 | 0.83 | PDPK1 (0.59) | PDPK1CNR1HPGDALDH1A1PLAAT3 | |
| SCHEMBL586345 | 0.83 | PDPK1 (0.59) | PDPK1CNR1HPGDALDH1A1PLAAT3 | |
| SCHEMBL2831742 | 0.82 | MPO (0.54) | HPGDALDH1A1POLBCYP1A2CYP3A4 | |
| SCHEMBL28812133 | 0.82 | MEN1 (0.45) | EPHX1ALDH1A1POLB | |
| SCHEMBL29858435 | 0.81 | IDO1 (0.52) | PDPK1CNR1IDO1HTTGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409917-B2 | Heterocyclic amide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-08-09 | — | — | US | claimed |
| EP-2804865-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-23 | — | — | EP | claimed |
| US-20150025075-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-01-22 | — | — | US | claimed |
| EP-2804865-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2014-11-26 | — | — | EP | claimed |
| WO-2013108227-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-25 | — | — | WO | claimed |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | claimed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | claimed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | claimed |
| EP-2444120-B1 | Spirocyclic amiloride analogues as ENac blockers | NOVARTIS AG (CH) | 2017-09-27 | — | — | EP | disclosed |
| US-9643983-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2017-05-09 | — | — | US | disclosed |
| US-9409917-B2 | Heterocyclic amide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-08-09 | — | — | US | disclosed |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| EP-2804865-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-23 | — | — | EP | disclosed |
| US-9139586-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2015-09-22 | — | — | US | disclosed |
| WO-1997049690-A1 | A METHOD FOR TREATING MENIERE'S DISEASE | MERCK & CO., INC. (US) | 1997-12-31 | — | — | WO | disclosed |
| EP-0731803-A4 | NOVEL FURANODIAZEPINES | MERCK & CO INC (US) | 1997-06-18 | — | — | EP | disclosed |
| CN-1142184-A | Antiarrhythmic benzodiazepines * | MERCK & CO INC (US) | 1997-02-05 | — | — | CN | disclosed |
| EP-0731803-A1 | NOVEL FURANODIAZEPINES | MERCK & CO. INC. (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5453424-A | Furanodiazepines | MERCK & CO., INC. (US) | 1995-09-26 | — | — | US | disclosed |
| WO-1995014695-A1 | NOVEL FURANODIAZEPINES | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025075-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX1, P2RX3 | PDPK1 2198/4885CNR1 23/4885IDO1 1408/4885 |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | SCNN1B, SCNN1A, SCNN1G | PDPK1 4279/4885CNR1 304/4885IDO1 4616/4885 |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | PDPK1 2290/4885CNR1 4339/4885IDO1 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.